
IndraLab
Statements
reach
"16
,
24
,
30
,
58
Reports of the effects of agonist drug molecules exhibiting type 3 or 4 properties for the pharmacological management of diLQTS and cLQTS are by comparison scarce,
22
,
59
although they have been reported to increase the PRRP and shorten the QT interval but potentially to the point of triggering arrhythmia such as the type 3 hERG activator mallotoxin or type 4 PD118057."